Bilastine
- Generic Name
- Bilastine
- Brand Names
- Blexten
- Drug Type
- Small Molecule
- Chemical Formula
- C28H37N3O3
- CAS Number
- 202189-78-4
- Unique Ingredient Identifier
- PA1123N395
- Background
Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.
- Indication
For symptomatic relief of nasal and non-nasal symptoms of seasonal rhinitis in patients 12 years of age and older and for symptomatic relief in chronic spontaneous urticaria in patients 18 years of age and older .
- Associated Conditions
- Chronic Spontaneous Urticaria, Seasonal Allergic Rhinitis
- Associated Therapies
- -
Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2012-09-26
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 36
- Registration Number
- NCT01081574
- Locations
- 🇩🇪
Universitäts-Hautklinik, Kiel, Germany
🇦🇺Princess Margaret Hospital for Children, Subiaco, Western Australia, Australia
🇦🇺Royal Children's Hospital, Parkville, Victoria, Australia
Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR
- Conditions
- Interventions
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 805
- Registration Number
- NCT00574379
- Locations
- 🇺🇸
Lovelace Scientific Resources, Austin, Texas, United States
🇺🇸Live Oak Allergy and Asthma, San Antonio, Texas, United States
🇺🇸MetaClin Research Inc., Austin, Texas, United States
PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)
- Conditions
- Interventions
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 502
- Registration Number
- NCT00574210
- Locations
- 🇨🇦
Allied Research International - Cetero Research, Mississauga, Ontario, Canada
Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis
- Conditions
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 683
- Registration Number
- NCT00504933
Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 522
- Registration Number
- NCT00421109
- Locations
- 🇧🇪
Centre nº 204, Gent, Belgium
🇦🇷Centre nº 107, Buenos Aires, Argentina
🇵🇱Centre nº 507, Krakow, Poland
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber
- Conditions
- Interventions
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 75
- Registration Number
- NCT00420082
- Locations
- 🇦🇹
Allergy Center Vienna West, Vienna, Austria
A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine
- Conditions
- Interventions
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 30
- Registration Number
- NCT00419783
- Locations
- 🇺🇸
MDS Pharma Services, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.